**Table S1.** Search Strategy**. Updated on June 2023**

|  |  |  |
| --- | --- | --- |
| **Set** | **PubMed** | **Results** |
| #1 | ("Ebstein Anomaly"[Mesh]) OR (Anomaly AND Ebstein\*) OR (Ebstein\* AND Malformation) OR (Familial AND Ebstein\* AND Anomaly) | 2,896 |
| #2 | ("Prenatal Diagnosis"[Mesh]) OR ((Prenatal OR Antenatal OR Intrauterine OR fetal) AND (Diagnos\* OR Screen\* OR Imaging\*)) | 203,485 |
| #3 | #1 AND #2 | **242** |
| **Set** | **Scopus** | **Results** |
| #1 | TITLE-ABS-KEY((Anomaly AND Ebstein\*) OR (Ebstein\* AND Malformation) OR (Familial AND Ebstein\* AND Anomaly)) | 4,199 |
| #2 | ALL(("Prenatal Diagnosis"[Mesh]) OR (Prenatal OR Antenatal OR Intrauterine OR fetal) AND (Diagnos\* OR Screen\* OR Imaging\*)) | 777,976 |
| #3 | ALL (Severe) | 3,496,004 |
| #4 | #1 AND #2 AND #3 | **315** |
| **Set** | **Web of Science** | **Results** |
| #1 | ALL=((Anomaly AND Ebstein\*) OR (Ebstein\* AND Malformation) OR (Familial AND Ebstein\* AND Anomaly)) | 54,379 |
| #2 | ALL=(("Prenatal Diagnosis"[Mesh]) OR (Prenatal OR Antenatal OR Intrauterine OR fetal) AND (Diagnos\* OR Screen\* OR Imaging\*)) | 114,176 |
| #3 | #1 AND #2 | **162** |

**Table S2.** Risk of bias assessment using Newcastle Ottawa Scale (NOS)1 for cohort studies and Joanna Briggs Institute (JBI) risk of bias scale for case reports and series.2

**NOS**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **First Author** | **Selection** | **Comparability** | **Outcome** | **Total** |
| Presentiveness of the exposed cohort | Selection of the non-exposed cohort | Ascertainment of exposure | Interested outcome not presented at the beginning | Assessment of outcome | Enough Follow-up | Adequacy of follow-up |
| Barre, 2012 | \* | \* | \* | \* |  | \* | \* | \* | 7 |
| Freud, 2015 | \* | \* | \* | \* | \* | \* | \* | \* | 8 |
| Gottschalk, 2017 | \* | \* | \* | \* |  | \* | \* | \* | 7 |
| Lasa, 2012 | \* | \* | \* | \* |  | \* | \* | \* | 7 |
| Masoller, 2020 | \* | \* | \* | \* |  | \* | \* | \* | 7 |
| Selamet Tierney, 2017 | \* | \* | \* | \* |  | \* | \* | \* | 7 |
| Sharland, 1991 | \* | \* | \* | \* |  | \* | \* | \* | 7 |
| Torigoe, 2020 | \* | \* | \* | \* |  | \* | \* | \* | 7 |
| Wertaschnigg, 2016 | \* | \* | \* | \* | \* | \* | \* | \* | 8 |

**JBI case series**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **First author** | **Were there clear criteria for inclusion in the caseseries?** | **Was the condition measured in a standard, reliableway for all participants included in the case series?** | **Were valid methods used for identification of thecondition for all participants included in the caseseries?**  | **Did the case series have consecutive inclusion ofparticipants?**  | **Did the case series have complete inclusion ofparticipants?** | **Was there clear reporting of the demographics ofthe participants in the study?**  | **Was there clear reporting of clinical information ofthe participants?**  | **Were the outcomes or follow up results of casesclearly reported?**  | **Was there clear reporting of the presentingsite(s)/clinic(s) demographic information?**  | **Was statistical analysis appropriate?** | **Overall** |
| Freud, 2021 | Yes | Yes | Yes | Not clear | Yes | Yes | Yes | Yes | Yes | Yes | 8 |
| Satomi, 1994 | No | Yes | Yes | Not clear | Yes | Yes | Yes | Yes | Yes | Not clear | 7 |
| Torigoe, 2019 | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 9 |

**JBI case reports**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **First Author** | **Were patient’s demographic characteristics clearly described?**  | **Was the patient’s history clearly described and presentedas a timeline?**  | **Was the current clinical condition of the patient onpresentation clearly described?**  | **Were diagnostic tests or assessment methods and theresults clearly described?** | **Was the intervention(s) or treatment procedure(s) clearlydescribed?**  | **Was the post-intervention clinical condition clearlydescribed?**  | **Were adverse events (harms) or unanticipated eventsidentified and described?** | **Does the case report provide takeaway lessons?** | **Overall** |
| Gill, 2021 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | 7 |
| Hakim, 2013 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 8 |
| Inamura, 2020 | No | Yes | Yes | Yes | Yes | Yes | No | Yes | 6 |
| Lopes, 2021 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | 7 |
| Rato, 2019 | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | 7 |
| Sasikumar, 2015 | Yes | No | Yes | Yes | Yes | No | Yes | No | 5 |
| Suneja, 1996 | No | Yes | Yes | Yes | Yes | Yes | No | Yes | 6 |
| Tongsong, 2005 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | 7 |
| Tsukimori, 2021 | Yes | No | No | Yes | Yes | Yes | Yes | Yes | 6 |